Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Syros Pharmaceuticals (0LC7) Share Price & Analysis

1 Followers

0LC7 Stock Chart & Stats

$0.00$0.00(0.00%)
At close: 2:30 PM GMT
$0.01$0.02$0.03Apr 22May 6May 19Jun 2Jun 16Jun 30Jul 14
Day’s Range
$0.01 - $0.01
52-Week Range
$0.00 - $0.31
Previous Close
$0.02
Volume
N/A
Average Volume (3M)
14.92K
Market Cap
$2,683
Enterprise Value
$86.52M
Total Cash (Recent Filing)
$58.27M
Total Debt (Recent Filing)
$60.23M
Price to Earnings (P/E)
0.0
Beta
68.42
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Market Opportunity

The significant market potential for tamibarotene provides a substantial growth opportunity, positioning Syros to capture a large share of the higher-risk MDS therapeutics market.

Advancement Of Tamibarotene

Successful advancement of tamibarotene could establish it as a new standard of care, significantly enhancing Syros' competitive position in the oncology market.

Reduction In Net Loss

The significant reduction in net loss indicates improved financial management and operational efficiency, enhancing long-term sustainability.

Bears Say

Financial Instability

The negative equity position indicates financial instability, posing risks to Syros' ability to fund operations and invest in growth initiatives.

Lack Of Revenue

The absence of revenue highlights challenges in monetizing its pipeline, which could hinder long-term financial viability and growth prospects.

Cash Depletion

The rapid decrease in cash reserves limits Syros' financial flexibility, potentially impacting its ability to sustain operations and fund R&D activities.

Syros Pharmaceuticals News

0LC7 FAQ

What was Syros Pharmaceuticals’s price range in the past 12 months?
Syros Pharmaceuticals lowest share price was $0.00 and its highest was $0.31 in the past 12 months.
What is Syros Pharmaceuticals’s market cap?
Syros Pharmaceuticals’s market cap is $2,683.
When is Syros Pharmaceuticals’s upcoming earnings report date?
Syros Pharmaceuticals’s next earnings report is estimated for Jul 31, 2025 (not yet confirmed), which is 472 days ago.
How were Syros Pharmaceuticals’s earnings last quarter?
Syros Pharmaceuticals released its earnings results on May 01, 2025. The company reported -$0.38 earnings per share for the quarter.
Is Syros Pharmaceuticals overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Syros Pharmaceuticals pay dividends?
Syros Pharmaceuticals does not currently pay dividends.
What is Syros Pharmaceuticals’s EPS estimate?
Syros Pharmaceuticals’s EPS estimate is -0.24.
How many shares outstanding does Syros Pharmaceuticals have?
Syros Pharmaceuticals has 26,832,457 shares outstanding.
What happened to Syros Pharmaceuticals’s price movement after its last earnings report?
Syros Pharmaceuticals reported an EPS of -$0.38 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Syros Pharmaceuticals?
Hedge funds hold Syros Pharmaceuticals shares: the largest hedge-fund position in Syros Pharmaceuticals is 877,404,171 shares, and hedge funds decreased their holdings by 251.3K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology